ResMed Inc. (RMD) Director Peter C. Farrell Sells 118,392 Shares

ResMed Inc. (NYSE:RMD) Director Peter C. Farrell sold 118,392 shares of the firm’s stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $82.70, for a total value of $9,791,018.40. Following the transaction, the director now directly owns 306,615 shares of the company’s stock, valued at approximately $25,357,060.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

ResMed Inc. (RMD) opened at $84.00 on Tuesday. ResMed Inc. has a fifty-two week low of $57.45 and a fifty-two week high of $87.81. The firm has a market capitalization of $11,786.54, a price-to-earnings ratio of 28.94, a P/E/G ratio of 1.85 and a beta of 0.79. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.72 and a quick ratio of 3.86.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The firm had revenue of $523.66 million for the quarter, compared to analysts’ expectations of $506.08 million. During the same quarter last year, the firm earned $0.62 earnings per share. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. equities analysts forecast that ResMed Inc. will post 3 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Investors of record on Thursday, November 9th will be issued a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a yield of 1.67%. The ex-dividend date is Wednesday, November 8th. ResMed’s payout ratio is currently 56.68%.

TRADEMARK VIOLATION NOTICE: This report was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://ledgergazette.com/2017/11/14/resmed-inc-rmd-director-peter-c-farrell-sells-118392-shares.html.

Institutional investors have recently modified their holdings of the stock. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in ResMed by 17.3% in the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 42,898 shares of the medical equipment provider’s stock valued at $3,340,000 after acquiring an additional 6,316 shares during the last quarter. Delta Lloyd Asset Management N.V. acquired a new position in ResMed in the second quarter valued at $6,194,000. Prudential Financial Inc. raised its position in ResMed by 50.5% in the second quarter. Prudential Financial Inc. now owns 131,997 shares of the medical equipment provider’s stock valued at $10,279,000 after purchasing an additional 44,266 shares during the period. Victory Capital Management Inc. raised its position in ResMed by 21.4% in the second quarter. Victory Capital Management Inc. now owns 21,597 shares of the medical equipment provider’s stock valued at $1,682,000 after purchasing an additional 3,809 shares during the period. Finally, Raymond James Financial Services Advisors Inc. raised its position in ResMed by 2.9% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 47,056 shares of the medical equipment provider’s stock valued at $3,665,000 after purchasing an additional 1,306 shares during the period. Hedge funds and other institutional investors own 58.86% of the company’s stock.

Several equities research analysts have recently issued reports on RMD shares. BMO Capital Markets raised their price objective on ResMed from $61.00 to $70.00 and gave the stock a “market perform” rating in a report on Wednesday, August 2nd. Needham & Company LLC restated a “sell” rating on shares of ResMed in a report on Wednesday, August 2nd. Barclays PLC raised their price objective on ResMed from $68.00 to $70.00 and gave the stock an “underweight” rating in a report on Friday, October 27th. Zacks Investment Research cut ResMed from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Finally, Credit Suisse Group cut ResMed from an “outperform” rating to a “neutral” rating in a report on Wednesday, August 2nd. Four research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. ResMed has an average rating of “Hold” and a consensus price target of $67.57.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply